GlassScriptPhysician profile
Katie C Wadlington
NPI 1417445180
$6,281.83
in general payments reported to CMS, 2019-2025
23 companies · $2,279 in 2025
The $2,279 reported for 2025 was more than what 79% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $286 · 2023: $1,418 · 2024: $2,299 · 2025: $2,279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,924 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,924.21 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $973.94 | 2023-2025 | |
| Abbvie INC. | $723.83 | 2023-2025 | Skyrizi |
| Dermavant Sciences, INC. | $627.61 | 2022-2024 | Vtama |
| Lilly USA, LLC | $596.85 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $512.64 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $364.54 | 2022-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $345.78 | 2023-2025 | Dupixent, Libtayo |
| Amgen INC. | $316.50 | 2023-2025 | Otezla, Otezla |
| Ucb, INC. | $305.79 | 2022-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $293.59 | 2023-2025 | |
| Incyte Corporation | $275.72 | 2022-2024 | Opzelura |
| Sun Pharmaceutical Industries INC. | $249.58 | 2023-2025 | Odomzo, Blu-U, Ilumya |
| Leo Pharma INC. | $154.37 | 2024-2025 | Adbry |
| Arcutis Biotherapeutics, INC. | $152.73 | 2023-2025 | Zoryve |
| Pfizer INC. | $89.67 | 2022-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Botanix Sb INC | $71.55 | 2025 | Sofdra |
| Galderma Laboratories, L.P. | $57.82 | 2022-2025 | Nemluvio |
| Mayne Pharma Commercial LLC | $40.87 | 2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $39.52 | 2025 | Cabtreo, Jublia, Siliq |
| Kerecis Limited | $29.15 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Convatec INC. | $24.56 | 2025 | |
| Organogenesis INC. | $18.97 | 2024 | |
| Genentech USA, INC. | $16.25 | 2024 | Erivedge |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Wadlington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.